Kansas City Heart Rhythm Research Foundation Report issue

Foundation Phase 1 Phase 4

Organization Overview

First Clinical Trial
2020
NCT04473807
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Kansas City Heart Rhythm Institute | Kansas City Heart Rhythm Research Foundation

Active Ingredients

Drugs in Phase 4 Trials (1)

sotalol (betapace) (1 trial)

Drugs in Phase 1 Trials (3)

bupivacaine (Exparel) (1 trial)

ketamine (ketalar) (1 trial)

ketorolac (acuvail) (1 trial)

Drugs in Other Trials (1)

caffeine (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arrhythmias, Cardiac (Phase 4)

Atrial Fibrillation (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial APIs: 5